Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
Limited Edition Golden Llama is here! Check out how you can get one. Limited Edition Golden Llama is here! Check out how you can get one.
Offering SPR-BLI Services - Proteins provided for free!Get your ComboX free sample to test now!
Time Limited Offer: Welcome Gift for New Customers ! Shipping Price Reduction for EU Regions
>
Insights >
COVID-19 vaccine development and its implications for the future of vaccines The development of COVID-19 vaccines was an unprecedented achievement at a time of urgent medical need. We explore the novel technology platforms that went into their development and consider their long-term impact on vaccine research.
Ever since the first vaccine against smallpox in the late 1700s, vaccines have gained a reputation as a critical tool in preventing infectious diseases and curtailing their spread.
Many people around the world were hopeful that this track record of vaccines would provide a solution for what was a growing COVID-19 pandemic in early 2020. The subsequent role that vaccines played in combating the pandemic has cemented their status as the ‘first-line of defense’ against infectious diseases.
Conceptually, vaccines defend the body by triggering a manageable immune response by using a weakened or inactive part of a disease-carrying organism (referred to as the antigen) to imitate an infection. The antigen triggers the body’s immune system to produce antibodies, which help fight off subsequent actual infections of the disease.
This allows protection against the disease for a specific period of time – from months to years – depending on the immune system’s memory and the disease in question. Thus, vaccines help in managing infection rates, potentially preventing severe disease.
Click to read the full text: https://www.labiotech.eu/partner/future-of-vaccine-research-and-technology-after-covid/
This insight article is created by Labiotech.eu
Writer: Sudha Sundaram
Related Reading
2.ACROBiosystems announces the release of their latest BA.2.75 antigen products
This web search service is supported by Google Inc.